Drugs / aliskerin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01432106 Comparator | Feb 2011 → Dec 2012 | hypertensive disorder, metabolic syndrome X | University of Michigan | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aliskerin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01432106 ↗ |
| Known as | Tekturna (Aliskerin) | “Tekturna (Aliskerin)” NCT01432106 ↗ |
| Action | Inhibit | “Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels.” NCT01432106 ↗ |